DESOTO, Kan., Nov. 9, 2017
/PRNewswire/ -- Oncimmune USA
LLC, the U.S. subsidiary of Oncimmune Holdings plc (AIM: ONC.L), a
leading early cancer detection company developing and
commercializing its proprietary EarlyCDT® platform
technology, today announces its launch of a validated finger stick
collection capability for its EarlyCDT®-Lung test.
The EarlyCDT®-Lung test is a simple blood test that
aids pulmonologists and other physicians in risk assessment and can
detect lung cancer up to four years earlier than other
methods. It is also highly cost-effective.
"By introducing finger stick blood collection, we have created
an option that will increase the speed and simplicity with which
the EarlyCDT®-Lung test can be ordered and completed
with no loss of performance. We are confident that this will make
the test more accessible, especially in the US, so that more
physicians and their patients will benefit from its ability to
detect lung cancer early," said Geoffrey
Hamilton-Fairley, CEO, Oncimmune.
Sample collection for EarlyCDT–Lung is simple but
previously required a venous blood draw which for some physician
practices in the US requires the patient to visit a medical center
or blood draw center where a trained phlebotomist can draw a venous
sample. This adds costs, time and is sometimes inconvenient for
patients. Finger stick collection now gives physicians and patients
the option to collect samples easily in the physician's office or
even in the patient's home, thus making the entire process much
simpler and quicker. Validation studies showed excellent results
correlation between venous and finger stick sampling methods with
no loss of signal or efficacy. Patients will still have the option
of having a standard venous collection through a phlebotomist if
this is their preference.
How the EarlyCDT®-Lung Finger Stick
Collection Process Works
The
EarlyCDT®-Lung test finger stick sample collection
procedure simply requires the patient to pierce the skin of the
finger using the contact activated lancet that is supplied and then
collect sufficient blood drops into a small collection tube that is
returned to Oncimmune's CLIA-certified laboratory in Kansas in a bag supplied. Once submitted, the
result is reported to the physician in two to five days. The
EarlyCDT®-Lung test may be billed to Medicare and
most commercial insurance.
About Oncimmune
Oncimmune is a leading early cancer
detection company developing and commercializing its
proprietary EarlyCDT® platform technology. Oncimmune has pioneered
the development of autoantibody tests that can detect cancer up to
four years earlier than other methods and can be applied to a
very wide range of solid tumor types. The Company's first
product, EarlyCDT®-Lung, was launched in 2012,
as a CLIA test in the USA and
since then over 150,000 commercial tests have been
sold. EarlyCDT®-Lung is available through
physicians in the US and privately in the UK and other
regions. EarlyCDT®-Lung is being used in
the largest ever randomized trial for the early detection of lung
cancer using biomarkers, the National Health Service (NHS) Scotland
ECLS study of 12,210 high-risk
smokers. EarlyCDT® tests for liver and
ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing
facilities in the US, joined AIM in May
2016 under the ticker ONC.L. For more information,
visit www.oncimmune.com
View original
content:http://www.prnewswire.com/news-releases/launch-of-finger-stick-sample-collection-for-earlycdt-lung-300552866.html
SOURCE Oncimmune